The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT).
 
Won Kim
Honoraria - Dava Oncology
Consulting or Advisory Role - Bayer; Dendreon
Research Funding - Novartis
Travel, Accommodations, Expenses - Dendreon; Xcenda
 
Charles J. Ryan
Honoraria - Astellas Pharma; Janssen Oncology
Consulting or Advisory Role - Bayer; Millennium
Research Funding - BIND Biosciences; Karyopharm Therapeutics; Novartis
 
Li Zhang
No Relationships to Disclose
 
Jack Youngren
No Relationships to Disclose
 
John Wilton
No Relationships to Disclose
 
Joshi J. Alumkal
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Millennium (Inst); Novartis (Inst)
 
Tomasz M. Beer
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Novartis
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Research & Development (Inst); Medivation (Inst); OncoGenex (Inst); Sotio; Sotio (Inst)
 
Robert Baertsch
No Relationships to Disclose
 
Josh Stuart
No Relationships to Disclose
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)
 
Martin Gleave
Employment - OncoGenex
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Oncogenex
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen
Travel, Accommodations, Expenses - Amgen
 
Matthew Rettig
Consulting or Advisory Role - Bayer
Speakers' Bureau - Johnson & Johnson
Research Funding - GlaxoSmithKline
 
Robert Evan Reiter
Stock and Other Ownership Interests - Inanovate
Consulting or Advisory Role - Astellas Pharma
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst)
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)
 
Christopher P. Evans
Stock and Other Ownership Interests - Medivation; Oncogenex
Honoraria - Janssen Oncology; Medivation; Sanofi
Consulting or Advisory Role - Janssen Oncology; Medivation; Millennium
Speakers' Bureau - Janssen Oncology; Medivation; Sanofi
Research Funding - Medivation
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Medivation; Sanofi
 
Eric Jay Small
No Relationships to Disclose